your market intelligence analyst
Search Results
52 results
Your search is now limited to «Biosimilars» expert search.
Healio News 07/09/2019 11:00
CHICAGO — Debra Patt, MD, MPH, MBA, executive vice president of Texas Oncology and medical director of analytics for US Oncology Network and McKesson Specialty Health, spoke with HemOnc Today about how the introduction of the oncology care model has enhanced quality and increased value.
More from Healio News:
Market Exclusive 07/09/2019 02:14
COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) Files An 8-K Results of Operations and Financial ConditionItem 2.02 Coherus BioSciences, Inc. ExhibitEX-99.1 2 d771294dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Coherus BioSciences Announces Unaudited Second Quarter 2019 UDENYCA® Net Sales of $79 Million to $84 Million REDWOOD CITY,…To view the full exhibit click here About COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) Coherus BioSciences, Inc. is a late-stage […]. The post COHERUS BIOSCIENCES, INC. (NASDAQ:CHRS) Files An 8-K Results of Operations and Financial Condition appeared first on Market Exclusive . 06/30/2019 21:06
DGAP-News: Formycon AG / Key word(s): AGM/EGM/Miscellaneous. 01.07.2019 / 15:06. The issuer is solely responsible for the content of this announcement. Press Release // July 1, 2019. Formycon reports on Annual General Meeting 2019. - Shareholders approve all items on the agenda. - Ratification of the actions of the Management Board and Supervisory Board by a large majority. - Hermann Vogt re-elected as member of the Supervisory Board. &nbs...
More from
Vancouver Sun (Canada) 06/23/2019 21:00
On May 27, the B.C. government announced a policy that will forcibly switch thousands of patients, effective Nov. 22, with serious, chronic conditions from their current biologic medicines to lower-cost “biosimilar” treatments. The roughly 23,000 patients who will be affected include those with rheumatoid arthritis, plaque psoriasis, psoriatic arthritis, diabetes, Crohn’s Disease and ulcerative colitis. […]
GaBI Online 06/14/2019 07:23
Building on a number of studies on biosimilar infliximab for inflammatory bowel disease (IBD), a recent review shows switching to CT-P13 is safe, but more evidence is needed on switching back to originator and switching between biosimilars [1].
More from GaBI Online:
Business Wire 06/11/2019 18:01
MADRID--(BUSINESS WIRE)--Celltrion Healthcare today presented new findings at the Annual European Congress of Rheumatology (EULAR 2019) from a two-part study investigating the pharmacokinetics, efficacy and overall safety of CT-P13 SC in patients with RA during the treatment period of one year.
More from Business Wire:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications